Brief: Biovica Refocuses US Commercial Strategy, Terminates Deal With Tempus AI
BRIEF-Biovica Refocuses US Commercial Strategy, Terminates Deal With Tempus AI June 30 (Reuters) - Biovica International AB BIOVICb.ST:
REFOCUSES US COMMERCIAL STRATEGY AND TERMINATES AGREEMENT WITH TEMPUS AI
COLLABORATION WITH TEMPUS DID NOT RESULT IN COMMERCIAL LAUNCH OR REVENUE
TERMINATION DOES NOT AFFECT SAN DIEGO LAB, US CLINICAL ACTIVITIES, OR PHARMA SERVICES
Source text: ID:nMFN9S9B53
Further company coverage: [BIOVICb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb